Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 9
2004 3
2005 3
2006 5
2007 4
2008 10
2009 11
2010 18
2011 13
2012 17
2013 32
2014 31
2015 25
2016 24
2017 37
2018 39
2019 27
2020 38
2021 46
2022 41
2023 47
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

435 results

Results by year

Filters applied: . Clear all
Page 1
KMT2C deficiency promotes small cell lung cancer metastasis through DNMT3A-mediated epigenetic reprogramming.
Na F, Pan X, Chen J, Chen X, Wang M, Chi P, You L, Zhang L, Zhong A, Zhao L, Dai S, Zhang M, Wang Y, Wang B, Zheng J, Wang Y, Xu J, Wang J, Wu B, Chen M, Liu H, Xue J, Huang M, Gong Y, Zhu J, Zhou L, Zhang Y, Yu M, Tian P, Fan M, Lu Z, Xue Z, Zhao Y, Yang H, Zhao C, Wang Y, Han J, Yang S, Xie D, Chen L, Zhong Q, Zeng M, Lowe SW, Lu Y, Liu Y, Wei Y, Chen C. Na F, et al. Among authors: lu y. Nat Cancer. 2022 Jun;3(6):753-767. doi: 10.1038/s43018-022-00361-6. Epub 2022 Apr 21. Nat Cancer. 2022. PMID: 35449309 Free PMC article.
SEL1L-HRD1 endoplasmic reticulum-associated degradation controls STING-mediated innate immunity by limiting the size of the activable STING pool.
Ji Y, Luo Y, Wu Y, Sun Y, Zhao L, Xue Z, Sun M, Wei X, He Z, Wu SA, Lin LL, Lu Y, Chang L, Chen F, Chen S, Qian W, Xu X, Chen S, Pan D, Zhou Z, Xia S, Hu CA, Liang T, Qi L. Ji Y, et al. Among authors: lu y. Nat Cell Biol. 2023 May;25(5):726-739. doi: 10.1038/s41556-023-01138-4. Epub 2023 May 4. Nat Cell Biol. 2023. PMID: 37142791 Free PMC article.
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations.
Lu S, Dong X, Jian H, Chen J, Chen G, Sun Y, Ji Y, Wang Z, Shi J, Lu J, Chen S, Lv D, Zhang G, Liu C, Li J, Yu X, Lin Z, Yu Z, Wang Z, Cui J, Xu X, Fang J, Feng J, Xu Z, Ma R, Hu J, Yang N, Zhou X, Wu X, Hu C, Zhang Z, Lu Y, Hu Y, Jiang L, Wang Q, Guo R, Zhou J, Li B, Hu C, Tong W, Zhang H, Ma L, Chen Y, Jie Z, Yao Y, Zhang L, Jie W, Li W, Xiong J, Ye X, Duan J, Yang H, Sun M, Sun C, Wei H, Li C, Ali SM, Miller VA, Wu Q. Lu S, et al. Among authors: lu y. J Clin Oncol. 2022 Sep 20;40(27):3162-3171. doi: 10.1200/JCO.21.02641. Epub 2022 May 17. J Clin Oncol. 2022. PMID: 35580297 Free PMC article. Clinical Trial.
Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer.
Wang XS, Bai YF, Verma V, Yu RL, Tian W, Ao R, Deng Y, Zhu XQ, Liu H, Pan HX, Yang L, Bai HS, Luo X, Guo Y, Zhou MX, Sun YM, Zhang ZC, Li SM, Cheng X, Tan BX, Han LF, Liu YY, Zhang K, Zeng FX, Jia L, Hao XB, Wang YY, Feng G, Xie K, Lu Y, Zeng M. Wang XS, et al. Among authors: lu y. J Natl Cancer Inst. 2023 Jun 8;115(6):742-748. doi: 10.1093/jnci/djac015. J Natl Cancer Inst. 2023. PMID: 35094066 Free PMC article. Clinical Trial.
Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer.
Lu Y, Xue J, Deng T, Zhou X, Yu K, Deng L, Huang M, Yi X, Liang M, Wang Y, Shen H, Tong R, Wang W, Li L, Song J, Li J, Su X, Ding Z, Gong Y, Zhu J, Wang Y, Zou B, Zhang Y, Li Y, Zhou L, Liu Y, Yu M, Wang Y, Zhang X, Yin L, Xia X, Zeng Y, Zhou Q, Ying B, Chen C, Wei Y, Li W, Mok T. Lu Y, et al. Nat Med. 2020 May;26(5):732-740. doi: 10.1038/s41591-020-0840-5. Epub 2020 Apr 27. Nat Med. 2020. PMID: 32341578 Clinical Trial.
Hydroxychloroquine in Stage 1 Type 1 Diabetes.
Libman I, Bingley PJ, Becker D, Buckner JH, DiMeglio LA, Gitelman SE, Greenbaum C, Haller MJ, Ismail HM, Krischer J, Moore WV, Moran A, Muir AB, Raman V, Steck AK, Toledo FGS, Wentworth J, Wherrett D, White P, You L, Herold KC; Type 1 Diabetes TrialNet Study Group. Libman I, et al. Among authors: you l. Diabetes Care. 2023 Nov 1;46(11):2035-2043. doi: 10.2337/dc23-1096. Diabetes Care. 2023. PMID: 37708415
Single-Soma Deep RNA sequencing of Human DRG Neurons Reveals Novel Molecular and Cellular Mechanisms Underlying Somatosensation.
Yu H, Usoskin D, Nagi SS, Hu Y, Kupari J, Bouchatta O, Cranfill SL, Gautam M, Su Y, Lu Y, Wymer J, Glanz M, Albrecht P, Song H, Ming GL, Prouty S, Seykora J, Wu H, Ma M, Rice FL, Olausson H, Ernfors P, Luo W. Yu H, et al. Among authors: lu y. bioRxiv [Preprint]. 2023 Sep 28:2023.03.17.533207. doi: 10.1101/2023.03.17.533207. bioRxiv. 2023. PMID: 36993480 Free PMC article. Preprint.
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial.
Zhou C, Wang Z, Sun Y, Cao L, Ma Z, Wu R, Yu Y, Yao W, Chang J, Chen J, Zhuang W, Cui J, Chen X, Lu Y, Shen H, Wang J, Li P, Qin M, Lu D, Yang J. Zhou C, et al. Among authors: lu y. Lancet Oncol. 2022 Feb;23(2):220-233. doi: 10.1016/S1470-2045(21)00650-1. Epub 2022 Jan 14. Lancet Oncol. 2022. PMID: 35038432 Clinical Trial.
435 results